← All bills
HR 1843In committeeHealthhouse
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Introduced Mar 5, 2025 by Rep. Neal P. Dunn
IntroducedCommitteeFloorCongressLaw
It's waiting on a committee vote to reach the full chamber. Most bills never leave this stage.
Latest action · Mar 5, 2025
Referred to the House Committee on Energy and Commerce.
What it does
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Summary by the Congressional Research Service.
Roll-call votes
No floor votes yet — it hasn't reached the floor of either chamber.